Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:C12Q1/68

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/138478METHOD FOR ANALYZING AND DIAGNOSING STATES RELATED TO METASTASIS/PRIMARY ONSET OF CANCER USING RNA MODIFICATION
WO 02.07.2020
Int.Class C12Q 1/6809
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6809Methods for determination or identification of nucleic acids involving differential detection
Appl.No PCT/JP2019/051560 Applicant OSAKA UNIVERSITY Inventor KONNO Masamitsu
The present disclosure provides a new method for analyzing states related to the metastasis/primary onset of cancer in a subject. The present disclosure provides a new method for analyzing states related to the metastasis/primary onset of cancer in a subject (for example, whether a subject has metastatic cancer, and whether a cancer is primary), on the basis of the discovery that cancer metastatic states are reflected in RNA modification information. The present disclosure makes it possible to analyze various biological states including cancer metastasis, and also makes it possible to determine the cancer to be treated as well as select a suitable treatment method.
2.WO/2020/133233PATHOGENIC MUTATION OF OSTEOGENESIS IMPERFECTA DISEASE AND DETECTION REAGENT THEREFOR
WO 02.07.2020
Int.Class C12Q 1/6883
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
Appl.No PCT/CN2018/124930 Applicant HUANG, Huan Inventor HUANG, Huan
Provided are a pathogenic mutation of osteogenesis imperfecta and a detection reagent therefor. For a mutant COL1A1 gene, single site mutation c.1822G>A (chr17:48270211) is related in the mutated COL1A1 gene, whereof the heterozygous mutation is pathogenic, the genetic mode is dominant inheritance, and for the amino acid change at p.Gly608Ser, the site mutation causes dyssynthesis of I-type collagen in connective tissue, so that a lesion is formed. Provided is a kit for detecting osteogenesis imperfecta, comprising a reagent for detecting the 1822bp-th site of a COL1A1 gene CDS or a reagent for detecting the 608-th amino acid site of a COL1A1 protein. The osteogenesis imperfecta disease can be diagnosed by detecting the pathogenic mutation (c.1822G>A on the COL1A1 gene).
3.WO/2020/134950GENE MUTATION/FUSION COMBINATION AND KIT FOR IDENTIFICATION OF BENIGN AND MALIGNANT PULMONARY NODULES
WO 02.07.2020
Int.Class C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
Appl.No PCT/CN2019/123432 Applicant JIANGSU MICRODIAG BIOMEDICINE TECHNOLOGY CO., LTD. Inventor WANG, Tao
Provided is a gene mutation/fusion combination using plasma as sample and using PCR technology to identify benign and malignant pulmonary nodules. The specific combination is: EGFR/KRAS or EGFR/KRAS/ALK/ROS1 or EGFR/KRAS/BRAF/ALK/ROS1 or EGFR/KRAS/BRAF/ALK/ROS1/STK11/NRAS/TP53/PIK3CA. Also provided is a relevant kit, and a layout of a detection system when the kit is used.
4.WO/2020/135689THERAPEUTIC AND PROPHYLACTIC USE OF MICROORGANISMS
WO 02.07.2020
Int.Class C12Q 1/68
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
Appl.No PCT/CN2019/129092 Applicant THE CHINESE UNIVERSITY OF HONG KONG Inventor NG, Siew Chien
Certain microorganism species in the gut and feces of fecal microbiota transplantation (FMT) donors can affect the outcome of FMT treatment. Thus, novel methods are provided for identifying subjects as suitable donor to optimize FMT outcome and for pre-treating donors and/or receipients for optimized FMT outcome. Also provided are kits and compositions for improving FMT outcome, including for specific purposes such as for weight loss or cholesterol reduction.
5.WO/2020/135862TUMOR MARKER STAMP-EP5 BASED ON METHYLATED MODIFICATION
WO 02.07.2020
Int.Class C12N 15/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
Appl.No PCT/CN2019/129838 Applicant SHANGHAI EPIPROBE BIOTECHNOLOGY CO., LTD. Inventor LI, Zhenyan
The present invention provides a methylated tumor marker STAMP-EP5 and an application thereof, relating to the technical field of disease diagnosis markers. The present invention further provides an application of methylated tumor marker STAMP-EP5 in the preparation of tumor diagnostic reagents.
6.WO/2020/136216METHODS OF IDENTIFYING SUBJECTS HAVING OR AT RISK OF HAVING A COAGULATION RELATED DISORDER
WO 02.07.2020
Int.Class C12Q 1/6883
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
Appl.No PCT/EP2019/087038 Applicant INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Inventor TREGOUET, David-Alexandre
Coagulation factor V (FV) plays an important and dual role in the regulation of blood coagulation by exhibiting both pro- and anticoagulant functions. In order to detect novel genetic loci participating to the regulation of Factor V (FV) plasma levels, the inventors conducted the first Genome Wide Association Study on this hemostatic phenotype in a sample of 510 individuals and replicated the main findings in an independent samples of 1156 individuals. In addition to genetic variations at the F5 locus, they identified novel associations at the PLXDC2 locus with the PLXDC2 rs927826 polymorphism explaining ~3.7% (p 7.5 10 -15 in the combined discovery and replication samples) of the variability of FV plasma levels. SiRNA experiments in human hepatocellular carcinoma cell line confirmed the role of PLXDC2 in modulating factor F5 gene expression. Accordingly, detecting a genetic variant in the PLXDC2 gene would be suitable for identifying a subject having or at risk of having a coagulation related disorder.
7.WO/2020/138965METHOD FOR DIAGNOSIS OF PERIODONTAL DISEASE, AND COMPOSITION AND KIT THEREFOR
WO 02.07.2020
Int.Class G01N 33/68
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
Appl.No PCT/KR2019/018497 Applicant SUGENTECH, INC. Inventor KIM, Eunkyung
The present invention relates to a method for diagnosis of a periodontal disease. More particularly, a periodontal disease is diagnosed when an inflammatory disease marker including MMP-8, or a marker derived from a periodontal disease-causing strain is detected at an increased concentration, compared to a sample from a normal control. The detection of MMP-8 is separately performed for active MMP-8 and inactive MMP-8, whereby a diagnosis method and a composition and kit for diagnosis or prognosis prediction, which are of high accuracy, can be provided.
8.WO/2020/139021GENETIC MARKER FOR HELICOBACTER PYLORI-ASSOCIATED DISEASE
WO 02.07.2020
Int.Class C12Q 1/6883
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
Appl.No PCT/KR2019/018607 Applicant CJ CHEILJEDANG CORPORATION Inventor LEE, Dong Yun
The present application relates to a composition for diagnosing a Helicobacter pylori-associated disease and a use thereof, the composition comprising a formulation for measuring the expression level of a gene the expression of which is increased or decreased by infection with Helicobacter pylori.
9.WO/2020/139756METHODS AND COMPOSITIONS TO SELECT AND/OR PREDICT COTTON PLANTS RESISTANT TO FUSARIUM RACE-4- RESISTANCE IN COTTON
WO 02.07.2020
Int.Class C07H 21/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Appl.No PCT/US2019/067825 Applicant DOW AGROSCIENCES LLC Inventor ANDERSON, Timothy
This disclosure concerns methods and compositions for identifying cotton plants that have a Fusarium wilt Race 4 resistance trait. Some embodiments concern molecular markers to identify, select, and/or construct Fusarium wilt Race 4 resistant plants and germplasm, or to identify and counter select relatively susceptible plants. This disclosure also concerns cotton plants comprising a Fusarium wilt Race 4 resistance trait that are generated by methods utilizing at least one marker described herein.
10.WO/2020/132747COMPOSITION AND METHOD FOR SEGREGATING EXTRACELLULAR DNA IN BLOOD
WO 02.07.2020
Int.Class C12N 15/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
10Processes for the isolation, preparation or purification of DNA or RNA
Appl.No PCT/CA2019/051906 Applicant DELTADNA BIOSCIENCES INC Inventor BIRNBOIM, Hyman Chaim
A composition and method suitable for separating and segregating extracellular DNA in a cell-containing sample, in particular, a blood sample is described. The composition comprising a thixotropic barrier gel and a stabilizing agent in aqueous solution at a concentration of at least 400 mM is capable of establishing and maintaining separation between intracellular and extracellular DNA in blood over time by means of physical barrier wherein when the composition is mixed with whole blood and centrifuged, plasma is separated from the packed cell layer by the thixotropic barrier gel and the blood cells are separated away from the plasma.